CLPTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

ClearPoint Neuro, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026

$9.17+0.10 (+1.10%)

Close on Oct 19, 2026

Market cap: $276.63M
P/E (TTM): –
Dividend yield: –

ClearPoint Neuro, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31
Revenue	37	31	24	21	16	13	11	7.35	7.38	5.75	4.59	3.60	3.93	5.06	3.82	2.67
Cost of Revenue	14	12	10	7.02	5.18	3.71	3.94	2.43	2.90	2.64	1.99	1.93	1.42	0.56	0.66	0.02
Gross Profit	23	19	14	14	11	9.12	7.28	4.92	4.48	3.11	2.61	1.68	2.51	4.50	3.16	2.65
Research & Development	14	12	12	11	9.28	4.69	2.81	2.31	2.81	2.63	1.96	3.30	2.92	2.48	4.25	5.68
Selling, General & Admin	16	12	12	9.61	8.00	5.27	4.30	4.33	4.05	4.19	8.37	8.04	7.06	6.03	4.83	4.70
Selling & Marketing	16	14	13	9.36	7.22	5.38	4.76	3.53	3.96	3.78	–	–	–	–	–	–
Total Costs & Expenses	–	–	–	–	–	–	–	–	–	–	–	–	11	8.19	9.74	12
Operating Income	-24	-20	-22	-16	-13	-6.22	-4.59	-5.25	-6.34	-7.49	-8.97	-5.32	-7.47	-3.13	-5.92	-9.52
Interest Expense	2.39	0.52	–	0.08	0.97	1.44	0.96	0.98	0.87	1.05	1.26	1.02	0.50	2.59	2.50	1.59
Interest & Investment Income	1.21	1.39	–	–	–	–	–	–	–	0.01	0.02	0.01	0.02	0.01	0.00	0.01
Other Non-Operating Income	-0.15	-0.04	-0.03	-0.02	-0.06	0.88	0.01	0.00	0.02	0.22	0.23	0.18	0.06	0.00	0.10	0.41
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	–	–	1.25	–	–	–	–	–
Asset Impairment Charges	–	–	–	–	–	–	–	–	–	–	–	0	0	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	–	–	0.00	0.00	–	–	–	–	–
Pretax Income	-25	-19	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Income Tax Expense	0.06	0.01	0.01	0	0	0	–	–	–	–	–	0	0	0	–	–
Net Income	-26	-19	-22	-16	-14	-6.78	-5.54	-6.16	-7.17	-8.07	-8.45	-4.52	-7.09	-5.88	-8.31	-9.45
EPS (Basic)(per share)	-0.90	-0.70	-0.90	-0.68	-0.69	-0.43	-0.42	-0.56	-0.93	-2.93	-4.48	-3.20	-4.80	-6.00	-20.80	-56.00
EPS (Diluted)(per share)	-0.90	-0.70	-0.90	-0.68	-0.69	-0.43	-0.42	-0.56	-0.93	-2.93	-4.48	-3.20	-4.80	-6.00	-20.80	-56.00
Shares Outstanding (Basic, Weighted)(shares)	28	27	25	24	21	16	13	11	7.74	2.75	1.88	1.48	1.43	1.01	0.40	0.17
Shares Outstanding (Diluted, Weighted)(shares)	28	27	25	24	21	16	13	11	7.74	2.75	1.88	1.48	1.43	1.01	0.40	0.17
EBITDA	-23	-19	-22	-16	-13	-5.89	-4.45	-5.14	-6.22	-7.33	-8.76	-4.94	-7.05	-2.71	-5.57	-9.25
Net Interest Income	–	0.87	0.39	-0.08	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 62.6%
Operating margin: -73.4%
Net margin: -81.8%
Return on equity, FY2025: -95.6%

Financial strength

Current ratio: 4.74
Debt to equity: 4.66
Debt to assets: 57.9%
Cash to current liabilities: 284.7%

Valuation

P/E ratio: –
Price to sales: 6.54
Price to book: 25.67
Dividend yield: –